The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque. - INTIMA

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Eligible are patients with either established cardiovascular disease or patients with a known elevated cardiovascular risk. Furthermore, age-matched healthy controls will be included.;Established cardiovascular disease (one or more of the following)
•- Coronary artery disease (e.g. myocardial infarction, angina pectoris, ischemic heart disease)
•- Carotid artery disease, previous stroke or transient ischemic attack
•- Aortic aneurysm
•- Peripheral artery disease;Elevated cardiovascular risk (one or more of the following)
•- BMI > 27
•- Metabolic syndrome
•- Diabetes mellitus type II
•- Hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg)
•- Reduced high-density lipoprotein (<1.03 mmol/l)
•- Elevated low-density lipoprotein (> 4.0 mmol/l);Healthy controls
•- Aged 40-80 years.
•- No cardiovascular risk factors.

•Active inflammatory diseases
•History of anaphylaxis or other hypersensitivity reactions
•History of iron overload
•History of renal failure or decreased renal function (eGFR <60 ml/min)
•History of abnormal liver function, or elevated liver enzymen (ALAT, ASAT > 3 times the upper limit of normal).
•Claustrophobia
•Metal-containing material in the body or attached to the body
•Planned diagnostic MRI scan in the next 6 months.

发起方